Literature DB >> 25268754

A new strategy to estimate levothyroxine requirement after total thyroidectomy for benign thyroid disease.

Vincenzo Di Donna1, Mario Giannotti Santoro, Chiara de Waure, Maria Pia Ricciato, Rosa Maria Paragliola, Alfredo Pontecorvi, Salvatore Maria Corsello.   

Abstract

BACKGROUND: The current approach for calculating the starting dose of levothyroxine (LT4) after total thyroidectomy is based on the patient's body weight (BW). The aim of the study was to identify the major predictive factors of LT4 requirement and to elaborate a new method to improve the accuracy of the LT4 starting dose after total thyroidectomy.
METHODS: The study consists of two parts. The first part consisted of the retrospective identification of 92 adult patients (retrospective cohort) who had undergone a total thyroidectomy for benign disease and who had begun LT4 treatment at a dose of 1.6 μg/kg/day. Adjustments to optimize the LT4 dose were then performed at the post-surgery follow-up on the basis of serum thyrotropin (TSH) levels. The results of this retrospective analysis were used to formulate a nomogram for a proper calculation of the LT4 starting dose that was then used prospectively in the second part of the study on 31 consecutive patients (prospective cohort).
RESULTS: At the first follow-up, 37 (40%) patients from the retrospective cohort were euthyroid. Univariate analysis indicated significant correlations between the optimal dose of LT4 and BW, body mass index (BMI), age, preoperative mean corpuscular volume, and free triiodothyronine (fT3). The optimal dose of LT4, analyzed for BMI and age, showed an inverse relationship with these two parameters, and ranged from 1.4 to 1.8 μg/kg/day. In the prospective cohort, the use of an age- and BMI-related nomogram improved the prediction of the optimal LT4 starting dose, with 68% of patients being euthyroid at the first follow-up compared to 41% of patients reported to have reached euthyroid state using the best strategy proposed in the literature.
CONCLUSIONS: This study confirms that BW is not the only variable for predicting LT4 requirement, as it decreases with the increase in age and BMI, probably due to the relative decrease of lean body mass. A new correlation between optimal dose and presurgical levels of fT3 and mean corpuscular volume was observed. We propose an easy and more efficient method of calculating LT4 starting dose after total thyroidectomy for benign disease.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25268754     DOI: 10.1089/thy.2014.0111

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  13 in total

1.  Is levothyroxine requirement the same for tablet and soft gel formulations?

Authors:  Vincenzo Di Donna; Rosa Maria Paragliola; Chiara de Waure; Giampaolo Papi; Alfredo Pontecorvi; Salvatore Maria Corsello
Journal:  Endocrine       Date:  2017-05-02       Impact factor: 3.633

2.  Optimal Thyroid Hormone Replacement.

Authors:  Jacqueline Jonklaas
Journal:  Endocr Rev       Date:  2022-03-09       Impact factor: 25.261

Review 3.  Pharmacokinetics and Clinical Implications of Two Non-Tablet Oral Formulations of L-Thyroxine in Patients with Hypothyroidism.

Authors:  Pierpaolo Trimboli; Stéphane Mouly
Journal:  J Clin Med       Date:  2022-06-16       Impact factor: 4.964

Review 4.  Hyperthyroidism.

Authors:  Amanda R Doubleday; Rebecca S Sippel
Journal:  Gland Surg       Date:  2020-02

Review 5.  Update on the treatment of hypothyroidism.

Authors:  Jacqueline Jonklaas
Journal:  Curr Opin Oncol       Date:  2016-01       Impact factor: 3.645

6.  Prospective Intervention of a Novel Levothyroxine Dosing Protocol Based on Body Mass Index after Thyroidectomy.

Authors:  Dawn M Elfenbein; Sarah Schaefer; Cynthia Shumway; Herbert Chen; Rebecca S Sippel; David F Schneider
Journal:  J Am Coll Surg       Date:  2015-10-21       Impact factor: 6.113

7.  The optimal dosing scheme for levothyroxine after thyroidectomy: A comprehensive comparison and evaluation.

Authors:  Nick A Zaborek; Andy Cheng; Joseph R Imbus; Kristin L Long; Susan C Pitt; Rebecca S Sippel; David F Schneider
Journal:  Surgery       Date:  2018-11-06       Impact factor: 3.982

8.  Variation in the biochemical response to l-thyroxine therapy and relationship with peripheral thyroid hormone conversion efficiency.

Authors:  John E M Midgley; Rolf Larisch; Johannes W Dietrich; Rudolf Hoermann
Journal:  Endocr Connect       Date:  2015-12       Impact factor: 3.335

9.  Incidental Papillary Thyroid Microcarcinoma in an Endemic Goiter Area.

Authors:  Emin Gürleyik; Gunay Gurleyik; Banu Karapolat; Ufuk Onsal
Journal:  J Thyroid Res       Date:  2016-02-02

Review 10.  Management of Graves Thyroidal and Extrathyroidal Disease: An Update.

Authors:  George J Kahaly
Journal:  J Clin Endocrinol Metab       Date:  2020-12-01       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.